Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

A new study published in JCI Insight suggests that interleukin-7 (IL-7), a key immune-boosting cytokine, may help critically ...

NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled promising preclinical and Phase 1 data for ratutrelvir, its ...

A new study by researchers from City St George's, University of London and the Ineos Oxford Institute for antimicrobial ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Federal officials cited the end of the Covid-19 pandemic in halting the research. But much of the work was focused on ...

This article examines the ethical implications of telemedicine in sexual medicine, focusing on privacy, informed consent, and healthcare equity. Despite its benefits in improving accessibility, ...